Lung Cancer Panel

Advanced genetic testing for personalised lung cancer treatment

Connect with Our Experts

To Book a Test,
Call 1800 296 9696

What Is a Lung Cancer Panel?

A Lung Cancer Panel is a comprehensive molecular test designed to detect genetic alterations in lung cancer cells, aiding in precise diagnosis and targeted treatment selection. This Lung Cancer Panel identifies driver mutations, gene rearrangements, and amplifications that contribute to tumour progression and treatment resistance. Molecular profiling through lung cancer genomic testing is now a standard approach in managing non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By identifying oncogenic driver mutations, a Lung Cancer Panel helps determine eligibility for targeted therapies, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and other precision medicine-based treatments.

Book a Test Now

Key Lung Cancer NGS Assays

Panel Type	Test Details
Comprehensive Tumor Panels (Tissue Biopsy)	TumourTrack Advance: Comprehensive Genomic Profiling, SNVs, CNVs & InDels – 395 genes+ Fusions: 190 genes + Microsatellite Instability (MSI) test + HRD+TMB. TumourTrack: Comprehensive Tumor Panel, SNVs, InDels & CNVs – 231 genes Fusions – 161 genes + TMB. Focused Tumour Panel by NGS: SNV, InDels, CNVs and fusions in 76 actionable genes that are clinically relevant for treatment decisions in multiple solid tumour types. Tumour Mutation Panel: SNVs, InDels and CNVs in relevant genes: 231 genes.
Lung Specific NGS Tests (Tissue Biopsy)	Lung Cancer Duo: Tissue biopsy+ Liquid biopsy : A dual- layered end-to-end Next-Generation Sequencing (NGS) approach for advanced lung cancer diagnostics. Parallel Tumor Tissue and Liquid Biopsy Testing for better characterization of molecular alterations. Covers 24 Actionable Genes for SNVs, InDels, CNVs and Fusions critical to Lung Cancer. Lung Cancer NGS Panel: SNVs & InDels - 18 genes, Fusions - 8 genes & CNVs - 3 genes and PDL 1 IHC Analysis (Clone SP263) / PDL 1 IHC Analysis (Clone SP142). Lung Cancer Gene Panel: SNVs & InDels - 6 genes, Fusions - 6 genes & CNVs - 3 genes and PD-L1 (Clone SP263) by IHC / PD-L1 (Clone SP263) by IHC + Microsatellite Instability (MSI) test. Non Small Cell Lung Cancer (NSCLC) Panel: SNVs and InDels - 14 genes & CNVs - 3 genes.
Liquid Biopsy	OncoTrack CGP: Comprehensive Genomic Profiling of Solid Tumors from Blood \| High precision multibiomarker test \| SNVs & InDels - 523 genes I CNVs - 59 genes I Fusion - 23 genes \| MSI \| TMB. OncoTrack Advance: 118 genes for all solid tumors detects SNVs, InDels & Fusions. LungTrack Advance: 24 genes for NSCLC (SNV & InDels in 24 genes and Fusions in 12 genes). Liquid Biopsy NGS Panel: SNVs and InDels in 33 genes & Fusions in 13 genes. OncoTrack Ultima: 118 genes for all solid tumors detects SNVs & InDels. Minimal Residual Disease (MRD) by NGS in Solid Tumours: SNVs and InDels in 118 tumor agnostic genes. Lung Cancer Panel: SNVs, InDels - 16 genes & Fusions - 9 genes.

Clinical Indications/Applications For Lung Cancer Panels

Newly Diagnosed Lung Cancer Patients: For identifying actionable driver mutations (e.g., EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK), guiding targeted therapy and immunotherapy options.
Patients With Advanced or Metastatic NSCLC: To select personalised treatment strategies and determine eligibility for targeted or immune checkpoint inhibitors (e.g., PD-L1 testing, TMB, MSI).
Patients With Insufficient or Inaccessible Tissue Samples: Liquid biopsy (cfDNA-based) offers a non-invasive alternative.
Patients on Targeted Therapy Showing Disease Progression: For detecting resistance mutations (e.g., EGFR T790M, C797S, MET amplification), enabling therapy switch decisions through repeat tissue or liquid biopsy testing.
Minimal Residual Disease (MRD) Monitoring: To help track tumor dynamics, early relapse, or treatment response in real time.

Specifications

Indications: Lung Cancer
Methodology: Next Generation Sequencing (NGS)
Sample Type: Tissue Biopsy: FFPE Tissue blocks (Minimum of 20% tumor content; Sample should be accompanied by an HPE Report and an IHC report)
Liquid Biopsy:: 2* 10ml of Peripheral blood in Streck tube.
Accuracy: Tissue Biopsy: 5% Variant Allele Frequency (VAF) for SNVs and InDels, >10 Spanning Reads for Fusions. Average Depth of Sequencing: >250X.
Liquid Biopsy: 0.2% VAF, >10 Spanning Reads for Fusions. Average Depth of Sequencing : >20000X (pre-UMI) and >2000X (post-UMI)
Coverage: SNVs, InDels, CNVs & Fusions.

Lung Cancer Tests Offered by MedGenome

Lung Cancer Duo (Tissue + Liquid) - 24 genes

Sample Type: Blood & FFPE
TAT: 14 working days
Test Code: MGM3549

Lung Cancer NGS Panel (18 Genes)

Sample Type: FFPE Tissue Block
TAT: 14 working days
Test Code: MGM3214

Lung Cancer NGS Panel (18 Genes) & PDL 1 IHC

Sample type: FFPE Tissue Block
TAT:14 working days
Test Code: MGM3216

Lung Cancer Gene Panel (SNVs, InDels & Fusions)

Sample Type: FFPE*
TAT: 14 working days
Test Code: MGM1492

Lung Cancer Gene Panel by NGS (SNVs, InDels & Fusions) + PD-L1 (SP263) by IHC

Sample Type: FFPE*
TAT: 14 working days
Test Code: MGM1493

Lung Cancer gene Panel by NGS (SNVs, InDels & Fusions)+ PD-L1 (SP263) by IHC + Microsatellite Instability (MSI) test

Sample Type: FFPE*
TAT: 14 working days
Test Code: MGM1496

Non Small Cell Lung Cancer (NSCLC) Panel (SNVs and InDels) Tissue in RNA Later

Sample Type: FFPE*
TAT: 21 working days
Test Code: MGM331

LungTrack Advance-Liquid Biopsy test by NGS (SNVs, InDels & Fusions)

Sample Type: Blood in Streck Tube
TAT: 14 working days
Test code: MGM2623

Key Highlights of MedGenome's Lung Cancer Panel Testing

Comprehensive Genetic Profiling

Detects single nucleotide variants (SNVs), insertions/deletions (InDels), gene fusions, and copy number variations (CNVs) across multiple lung cancer-associated genes.

Tumor Tissue & Liquid Biopsy Options

Offers both tumour tissue (FFPE) and blood-based (liquid biopsy) testing, enabling non-invasive detection of circulating tumour DNA (ctDNA) for patients who cannot undergo a biopsy.

Advanced Testing Techniques

Utilises Next-Generation Sequencing (NGS), Real-Time PCR, IHC, and Fluorescence In Situ Hybridisation (FISH) for high-accuracy mutation detection.

Fast Turnaround Time & Expert Support

Delivers rapid and precise results, supported by genetic counselling services to help patients and doctors understand the test findings and treatment options.

What is a Lung Cancer Panel?

A Lung Cancer Panel is a specialised test that helps detect genetic changes, also called mutations, in lung cancer cells. These mutations can influence how the cancer develops, spreads, and responds to different treatments. By analysing these genetic changes, doctors can determine the best-targeted therapy for a patient, helping them receive a more personalised treatment approach.

Book a Test Now

What Are the Different Types of Lung Cancer Panels?

Lung Cancer Panel Type	Description & Key Features
Lung cancer mutation panel	Descriptions: Detects key mutations, helping in treatment decisions. Key Features: - Identifies EGFR, ALK, KRAS, ROS1, BRAF, MET, among others. - Determines targeted therapy eligibility. - NGS-based platform.
Lung cancer gene panel	Description: Analyses multiple lung cancer genes. Key Features: - Detects common & rare mutations. - Helps in advanced cancer treatment. - Supports precision medicine.
Comprehensive lung panel test	Description: Provides a full genetic tumour profile. Key Features: - Covers wide cancer-related genes. - Uses Liquid Biopsy and Tumor Biopsy by NGS and IHC. - Detects drug resistance mutations.

How Does a Lung Cancer Panel Work?

A Lung Cancer Panel works by examining the genetic material a patient’s cancer cells. The test looks for gene mutations, rearrangements, and amplifications that could be driving the growth of lung cancer. These mutations provide important information about whether a patient may benefit from targeted therapies instead of conventional chemotherapy.

The Lung Cancer Panel Test is conducted using advanced technologies like Next-Generation Sequencing (NGS). This method helps identify mutations in genes like EGFR, KRAS, ALK, ROS1, BRAF, and MET, among other relevant mutations, which play a crucial role in guiding lung cancer treatment.

Who Should Consider a Lung Cancer Panel Test?

What Are the Benefits of Lung Cancer Panel Testing?

A Lung Cancer Panel Test provides several advantages for both patients and doctors by ensuring accurate diagnosis and effective treatment selection.

Personalised Treatment – The test identifies gene mutations that can help determine targeted therapy.
Early Detection of Drug Resistance – Some genetic mutations make certain treatments less effective. This Lung Cancer Panel testing helps find these resistance mutations early so that clinicians can modify the treatment plan for better prognosis.
Minimally Invasive Testing Options – Liquid biopsy-based Lung Cancer Panel Testing allows doctors to analyse cancer mutations using a simple blood sample, eliminating the need for a traditional tumour biopsy.
Faster & More Accurate Results – NGS-based lung cancer genomic testing provides a detailed report of multiple genetic mutations in a single test, making it more efficient than traditional methods.

How Is the Lung Cancer Panel Test Performed?

What Do the Results of a Lung Cancer Panel Mean?

The Lung Cancer Panel results help doctors understand how the cancer is behaving and which treatment options might be the most effective.

Positive Result: A specific mutation is found in genes like EGFR, ALK, ROS1, KRAS, or BRAF. This means the patient may be eligible for targeted therapy, which is more effective and has fewer side effects than chemotherapy.
Negative Result: No known mutations are detected in the tested genes. This means the patient may need to consider other treatment options, such as chemotherapy or immunotherapy.

Why Choose MedGenome for Lung Cancer Panel Testing?

How Is MedGenome’s Lung Cancer Panel Different From Other Tests?

Get Genetic Counselling by Our Experts

Connect with Our Experts

MedGenome Patient Stories

The couple had previously endured several miscarriages. Further investigations revealed that these losses were due to chromosomal abnormalities (aneuploidies) in the foetus. During their subsequent IVF...

Reproductive Health

Mr. and Mrs. Swamy’s Journey to Paren...

Reported first case of X chromosome variant detected by NIPT confirmed by karyotyping, missed by FISH. Savitha (name changed) a 24 year old from Delhi was...

Reproductive Health

Story of Savitha

Mr. Arjun (name changed) and Ms. Shilpa (name changed) are maternal cousins. They are planning to get married. There is no significant clinical history suggestive of...